Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis-Reference-Cited by-同舟云学术

Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis

Published:2015-07 Issue:7 Volume:2 Page:e271-e278
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Haas Andreas D,Keiser Olivia,Balestre Eric,Brown Steve,Bissagnene Emmanuel,Chimbetete Cleophas,Dabis François,Davies Mary-Ann,Hoffmann Christopher J,Oyaro Patrick,Parkes-Ratanshi Rosalind,Reynolds Steven J,Sikazwe Izukanji,Wools-Kaloustian Kara,Zannou D Marcel,Wandeler Gilles,Egger Matthias

Funder

National Institute of Allergy and Infectious Diseases

Swiss National Science Foundation

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference24 articles.

1. Diagnosis and management of antiretroviral-therapy failure in resource-limited settings in sub-Saharan Africa: challenges and perspectives;Harries;Lancet Infect Dis,2010

2. Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa;Fox;J Acquir Immune Defic Syndr,2012

3. Mortality after failure of antiretroviral therapy in sub-Saharan Africa;Keiser;Trop Med Int Health,2010

4. Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared;Keiser;PLoS Med,2008

5. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach,2010

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Health and budget impact, and price threshold for cost-effectiveness of lenacapavir for PrEP in Eastern and Southern Africa: a modeling analysis;2024-08-21

2. Cancer risk among people living with Human Immunodeficiency Virus (HIV) in Rwanda from 2007 to 2018;International Journal of Cancer;2024-08-11

3. HIV-1 subtype-specific drug resistance on dolutegravir-based antiretroviral therapy: protocol for a multicentre study (DTG RESIST);BMJ Open;2024-08

4. Predicting emergent Dolutegravir resistance in South Africa: A modelling study;2024-07-21

5. HIV-1 subtype-specific drug resistance on dolutegravir-based antiretroviral therapy: protocol for a multicentre longitudinal study (DTG RESIST);2024-05-24